These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

261 related articles for article (PubMed ID: 28708956)

  • 1. The power of combining adoptive cell therapy (ACT) and pathogen-boosted vaccination to treat solid tumors.
    Zander R; Cui W
    Hum Vaccin Immunother; 2017 Oct; 13(10):2269-2271. PubMed ID: 28708956
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chimeric Antigen Receptor T Cell Based Immunotherapy for Cancer.
    Li F; Zhang T; Cao L; Zhang Y
    Curr Stem Cell Res Ther; 2018; 13(5):327-335. PubMed ID: 29676233
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antigenic targets of CAR T Cell Therapy. A retrospective view on clinical trials.
    Arabi F; Torabi-Rahvar M; Shariati A; Ahmadbeigi N; Naderi M
    Exp Cell Res; 2018 Aug; 369(1):1-10. PubMed ID: 29758187
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CAR T Cell Therapy for Solid Tumors.
    Newick K; O'Brien S; Moon E; Albelda SM
    Annu Rev Med; 2017 Jan; 68():139-152. PubMed ID: 27860544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. CAR T-cell therapy of solid tumors.
    Yong CSM; Dardalhon V; Devaud C; Taylor N; Darcy PK; Kershaw MH
    Immunol Cell Biol; 2017 Apr; 95(4):356-363. PubMed ID: 28003642
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prospects to improve chimeric antigen receptor T-cell therapy for solid tumors.
    Jin C; Yu D; Essand M
    Immunotherapy; 2016 Dec; 8(12):1355-1361. PubMed ID: 28000533
    [TBL] [Abstract][Full Text] [Related]  

  • 7. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells.
    Ikeda H
    Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.
    Ott PA; Dotti G; Yee C; Goff SL
    Am Soc Clin Oncol Educ Book; 2019 Jan; 39():e70-e78. PubMed ID: 31099621
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies.
    Rodgers DT; Mazagova M; Hampton EN; Cao Y; Ramadoss NS; Hardy IR; Schulman A; Du J; Wang F; Singer O; Ma J; Nunez V; Shen J; Woods AK; Wright TM; Schultz PG; Kim CH; Young TS
    Proc Natl Acad Sci U S A; 2016 Jan; 113(4):E459-68. PubMed ID: 26759369
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors.
    Zhang BL; Qin DY; Mo ZM; Li Y; Wei W; Wang YS; Wang W; Wei YQ
    Sci China Life Sci; 2016 Apr; 59(4):340-8. PubMed ID: 26965525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CAR T-cell therapy effective in B acute lymphoblastic leukaemia.
    Wang M
    Lancet Oncol; 2017 Jun; 18(6):e314. PubMed ID: 28528746
    [No Abstract]   [Full Text] [Related]  

  • 12. [Adoptive transfer of T lymphocytes].
    Vié H; Clémenceau B
    Transfus Clin Biol; 2017 Sep; 24(3):256-262. PubMed ID: 28648732
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Engineering CAR T Cells with Biomaterials.
    Cancer Discov; 2017 Jul; 7(7):656-657. PubMed ID: 28500027
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reprogramming the tumor microenvironment to enhance adoptive cellular therapy.
    Beavis PA; Slaney CY; Kershaw MH; Gyorki D; Neeson PJ; Darcy PK
    Semin Immunol; 2016 Feb; 28(1):64-72. PubMed ID: 26611350
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced Cancer Immunotherapy by Chimeric Antigen Receptor-Modified T Cells Engineered to Secrete Checkpoint Inhibitors.
    Li S; Siriwon N; Zhang X; Yang S; Jin T; He F; Kim YJ; Mac J; Lu Z; Wang S; Han X; Wang P
    Clin Cancer Res; 2017 Nov; 23(22):6982-6992. PubMed ID: 28912137
    [No Abstract]   [Full Text] [Related]  

  • 16. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Axicabtagene ciloleucel for the treatment of relapsed/refractory B-cell non-Hodgkin's lymphomas.
    Sharma P; King GT; Shinde SS; Purev E; Jimeno A
    Drugs Today (Barc); 2018 Mar; 54(3):187-198. PubMed ID: 29771253
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects.
    Di S; Li Z
    Sci China Life Sci; 2016 Apr; 59(4):360-9. PubMed ID: 26968709
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antigen choice in adoptive T-cell therapy of cancer.
    Offringa R
    Curr Opin Immunol; 2009 Apr; 21(2):190-9. PubMed ID: 19297140
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells.
    Ramachandran M; Dimberg A; Essand M
    Semin Cancer Biol; 2017 Aug; 45():23-35. PubMed ID: 28257957
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.